The effect of potent iron chelators on the regulation of p53: Examination of the expression, localization and DNA-binding activity of p53 and the transactivation of WAF1

Carcinogenesis

Volumn 24, Issue 10, 2003, Pages 1601-1614

  Liang, S X ^a,b   Richardson, D R ^a,b  

^a CHILDREN S CANCER INSTITUTE AUSTRALIA FOR MEDICAL RESEARCH   (Australia)

^b HEART RESEARCH INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

2 HYDROXY 1 NAPHTHYLALDEHYDE ISONICOTINOYLHYDRAZONE; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLOHEXIMIDE; DACTINOMYCIN; DEFEROXAMINE; IRON CHELATING AGENT; LUCIFERASE; MESSENGER RNA; PROTEIN P21; PROTEIN P53; UNCLASSIFIED DRUG;

ARTICLE; BINDING SITE; CANCER INHIBITION; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CONTROLLED STUDY; DNA BINDING; DRUG STRUCTURE; ENZYME ACTIVITY; GENE CONSTRUCT; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DNA BINDING; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REGULATORY MECHANISM; TRANSACTIVATION;

BLOTTING, NORTHERN; BLOTTING, WESTERN; CELLS, CULTURED; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; DACTINOMYCIN; ELECTROPHORETIC MOBILITY SHIFT ASSAY; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, REPORTER; HUMANS; IRON CHELATING AGENTS; ISONIAZID; PROTEIN SYNTHESIS INHIBITORS; RNA, MESSENGER; TRANS-ACTIVATION (GENETICS); TRANSCRIPTION, GENETIC; TRANSFECTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0142154312     PISSN: 01433334     EISSN: None     Source Type: Journal    
DOI: 10.1093/carcin/bgg116     Document Type: Article

References (55)

1. Hershko,C. (1994) Control of disease by selective iron depletion: a novel therapeutic strategy utilizing iron chelators. Baillière's Clin. Haematol., 7, 965-1000.
2. Richardson,D.R. (2002) Iron chelators as therapeutic agents for the treatment of cancer. Crit. Rev. Oncol. Hematol., 42, 267-281.
3. Finch,R.A., Liu,M.-C., Grill,S.P., Rose,W.C., Loomis,R., Vasquez,K.M., Cheng,Y.-C. and Sartorelli,A.C. (2000) Triapine (3-aminopyridine-2-carboxaldehyde-thiosemicarbazone): a potent inhibitor of ribonucleotide reductase activity with broad spectrum antitumor activity. Biochem. Pharmacol., 59, 983-991.
4. Torti,S.V., Torti,F.M., Whitman,S.P., Brechbiel,M.W., Park,G. and Planalp,R.P. (1998) Tumor cell cytotoxicity of a novel metal chelator. Blood, 92, 1384-1389.
5. Rakba,N., Loyer,P., Gilot,D., Delcros,J.G., Glaise,D., Baret,P., Pierre,J.L., Brissot,P. and Lescoat,G. (2000) Antiproliferative and apoptotic effects of O-Trensox, a new synthetic iron chelator, on differentiated human hepatoma cell lines. Carcinogenesis, 21, 943-951.
6. Richardson,D.R., Tran,E.H. and Ponka,P. (1995) The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective anti-proliferative agents. Blood, 8, 4295-4306.
7. Gao,J. and Richardson,D.R, (2001) The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents, IV: the mechanisms involved in inhibiting cell-cycle progression. Blood, 98, 842-850.
8. Lovejoy,D.B. and Richardson,D.R. (2002) Novel "hybrid" iron chelators derived from aroylhydrazones and thiosemicarbazones demonstrate high anti-proliferative activity that is selective for tumor cells. Blood, 100, 666-676.
9. Richardson,D.R., Hefter,G.T., May,P.M., Webb,J. and Baker,E. (1989) Iron chelators of the pyridoxal isonicotinoyl hydrazone class III. Formation constants with calcium(II), magnesium(II) and zinc(II). Biol. Met., 2, 161-167.
10. Vitolo,M.L., Hefter,G.T., Clare,B.W. and Webb,J. (1990) Iron chelators of the pyridoxal isonicotinoyl hydrazone class Part 2. Formation constants with iron(III) and iron(II). Inorg. Chim. Acta, 170, 171-176.
11. Darnell,G. and Richardson,D.R. (1999) The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents III: the effect of the ligands on molecular targets involved in proliferation. Blood, 94, 781-792.
12. Levine,A.J. (1997) p53, the cellular gatekeeper for growth and division. Cell, 88, 323-331.
13. Gartel,A.L. and Tyner,A.L. (1999) Transcriptional regulation of the p21 (WAF1/CIP1) gene. Exp. Cell Res., 246, 280-289.
14. Lohrum,M.A. and Vousden,K.H. (2000) Regulation and function of the p53-related proteins: same family, different rules. Trends. Cell Biol., 10, 197-202.
15. An,W.G., Kanekal,M., Simon,M.C., Maltepe,E., Blagosklonny,M.V. and Neckers,L.M. (1998) Stabilization of wild-type p53 by hypoxia-inducible factor lalpha. Nature, 392, 405-408.
16. Abeysinghe,R.D., Greene,B.T., Haynes,R., Willingham,M.C., Turner,J., Planalp,R.P., Brechbiel,M.W., Torti,F.M. and Torti,S.V. (2001) p53-independent apoptosis mediated by tachpyridine, an anti-cancer iron chelator. Carcinogenesis, 22, 1607-1614.
17. Choi,A.M. and Alam,J. (1996) Heme oxygenase-1: function, regulation and implication of a novel stress-inducible protein in oxidant-induced lung injury. Am. J. Respir. Cell Mol. Biol., 15, 9-19.
18. Zhu,C., Huang,Y., Weydert,C.J., Oberley,L.W. and Domann,F.E. (2001) Constitutive activation of transcription factor AP-2 is associated with decreased MnSOD expression in transformed human lung fibroblasts. Antioxidants Redox Signaling, 3, 387-395.
19. Sun,Y., Bian,J., Wang,Y. and Jacobs,C. (1997) Activation of p53 transcriptional activity by 1,10-phenanthroline, a metal chelator and redox sensitive compound. Oncogene, 14, 385-393.
20. Hainaut,P. arid Milner,J. (1993) A structural role for metal ions in the "wild-type" conformation of the tumor suppressor protein p53. Cancer Res., 53, 1739-1742.
21. Hainaut,P. and Milner,J. (1993) Redox modulation of p53 conformation and sequence-specific DNA binding in vitro. Cancer Res., 53, 4469-4473.
22. Richardson,D.R. and Bernhardt,P. ( 1999) Crystal and molecular structure of 2-hydroxy-1-naphthylaldehyde isonicotinoyl hydrazone (NIH) and its iron (III) complex: an iron chelator with pronounced anti-tumor activity. J. Biol. Inorg. Chem., 4, 266-273.
23. Richardson,D.R. and Baker,E. (1992) Two mechanisms of iron uptake from transferrin by melanoma cells. The effect of desferrioxamine and ferric ammonium citrate. J. Biol. Chem., 267, 13972-13979.
24. Lassar,A.B., Davis,R.L., Wright,W.E., Kadesch,T., Murre,C., Voronova,A., Baltimore,D. and Weintraub,H. (1991) Funtional activity of myogenic HLH proteins requires hetero-oligomerization with E12/E47-like protein in vivo. Cell, 66, 305-315.
25. Bargonetti,J., Reynisdóttir,I., Friedman,P.N. arid Prives,C. (1992) Site-specific binding of wild-type p53 to cellular DNA is inhibited by SV40 T antigen and mutant p53. Genes Dev., 6, 1886-1898.
26. Russo,T., Zambrano,N., Esposito,F., Ammendola,R., Cimino,F., Fiscella,M., Jackman,J., O'Conner,P.M., Anderson,C.W. and Appella,E. (1995) A p53-independent pathway for activation of WAF1/CIP1 expression following oxidative stress. J. Biol. Chem., 270, 29386-29391.
27. WAF1/CIP1 gene by retinoic acid receptor. J. Biol. Chem., 271, 31723-31728.
28. WAF1/CIP1 expression in normal and neoplastic tissues. Cancer Res., 55, 2910-2919.
29. Davidoff,A.M., Pence,J.C., Shorter,N.A., Iglehart,J.D. and Marks,J.R. (1992) Expression of p53 in human neuroblastoma- and neuroepithelioma-derived cell lines. Oncogene, 7, 127-133.
30. Ashcroft,M., Taya,Y. and Vousden,K.H. (2000) Stress signals utilize multiple pathways to stabilize p53. Mol. Cell. Biol., 20, 3224-3233.
31. Tweddle,D.A., Malcolm,A.J., Cole,M., Pearson,A.D. and Lunec,J. (2001) p53 cellular localization and function in neuroblastoma. Evidence for defective G1 arrest despite WAF1 induction in MYCN-amplified cells. Am. J. Pathol., 158, 2067-2077.
32. Greenberg,M.E. arid Ziff,E.B. (1984) Stimulation of 3T3 cells induces transcription of the c-fos proto-oncogene. Nature, 311, 433-438.
33. Groudine,M., Peretz,M. and Weinbraub,H. (1981) Transcriptional regulation of hemoglobin switching in chicken embryos. Mol. Cell. Biol., 1, 281-298.
34. Richardson,D.R. and Milnes,K. (1997) The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents II: the mechanism of action of ligands derived from salicylaldehyde benzoyl hydrazone and 2-hydroxy-1-naphthylaldehyde benzoyl hydrazone. Blood, 89, 3025-3038.
35. Becker,E., Lovejoy,D.B., Greer,J.M., Watts,R. and Richardson,D.R. (2003) Novel aroylhydrazone iron chelators differ in their iron chelation efficacy and anti-proliferative activity: identification of a new class of potential anti-proliferative agents. Br. J. Pharmacol., 138, 819-830.
36. 1 phase of the cell cycle. Cancer Res., 53, 3968-3975.
37. Hupp,T.R. and Lane,D.P. (1994) Allosteric activation of latent p53 tetramers. Curr. Biol., 4, 865-875.
38. Linke,S.P., Clarkin,K.C., Di Leonardo,A., Tsou,A. and Wahl,G.M. (1996) A reversible, p53-dependent G0/G1 cell cycle arrest induced by ribonucleotide depletion in the absence of detectable DNA damage. Genes Dev., 10, 934-947.
39. Ayed,A., Mulder,F.A., Yi,G.S., Lu,Y., Kay,L.E. and Arrowsmith,C.H. (2001) Latent and active p53 are identical in conformation. Nature Struct. Biol., 8, 756-760.
40. Unger,T., Mietz,J.A., Scheffner,M., Yee,C.L. and Howley,P.M. (1993) Functional domains of wild-type and mutant p53 proteins involved in transcriptional regulation, transdominant inhibition and transformation suppression. Mol. Cell. Biol., 13, 5186-5194.
41. Martell,A.E. and Smith,R.M. (1977) Critical Stability Constants. Plenum Press, New York, NY.
42. Esposito,F., Cuccovillo,F., Vanoni,M., Cimino,F., Anderson,C.W., Appella,E. and Russo,T. (1997) Redox-mediated regulation of p21(waf1/cip1) expression involves a post-transcriptional mechanism and activation of the mitogen-activated protein kinase pathway. Eur. J. Biochem., 245, 730-737.
43. Johannessen,L.E., Knardal,S.L. and Madshus,I.H. (1999) Epidermal growth factor increases the level of the cyclin-dependent kinase (CDK) inhibitor p21/CIP1 (CDK-interacting protein 1) in A431 cells by increasing the half-lives of the p21/CIP1 transcript and the p21/CIP1 protein. Biochem. J., 337, 599-606.
44. Akashi,M., Osawa,Y., Koeffler,H.P. and Hachiya,M. (1999) p21WAF1 expression by an activator of protein kinase C is regulated mainly at the post-transcriptional level in cells lacking p53: important role of RNA stabilization. Biochem. J., 337, 607-616.
45. Park,J.S., Qiao,L., Gilfor,D., Yang,M.Y., Hylemon,P.B., Benz,C., Darlington,G., Firestone,G., Fisher,P.B. and Dent,P. (2000) A role for both Ets and C/EBP transcription factors and mRNA stabilization in the MAPK-dependent increase in p21 (Cip1/WAF1/mda6) protein levels in primary hepatocytes. Mol. Biol. Cell, 11, 2915-2932.
46. Green,D.A., Antholine,W.E., Wong,S.J., Richardson,D.R. and Chitambar,C.R. (2001) Ribonucleotide reductase as a preferential target for the inhibition of leukemic cell growth by 311, a novel iron chelator of the pyridoxal isonicotinoyl hydrazone class. Clin. Cancer Res., 7, 3574-3579.
47. Yoon,G., Kim,H.J., Yoon,Y.-S., Cho,H., Lim,L.K. and Lee,J.-H. (2002) Iron chelation-induced senescence-like growth arrest in hepatocyte cell lines: association of transforming growth factor β1 (TGF-β1)-mediated p27Kip1 expression. Biochem. J., 366, 613-621.
48. WAF1/CIP1 , but paradoxically inhibit translation: a potential mechanism of cell cycle dysregulation. Carcinogenesis, 24, 1045-1058.
49. Alcantara,O., Kalidas,M., Baltathakis,I. and Boldt,D.H. (2001) Expression of multiple genes regulating cell cycle and apoptosis in differentiating hematopoietic cells is dependent on iron. Exp. Hematol., 29, 1060-1069.
50. Blagosklonny,M.V., Wu,G.S., Omura,S. and El-Deiry,W.S. (1996) Proteasome-dependent regulation of p21WAF1/CIP1 expression. Biochem. Biophys. Res. Commun., 227, 564-569.
51. Sheaff,R.J., Singer,J.D., Swanger,J., Smitherman,M., Roberts,J.M. and Clurman,B.E. (2000) Proteasomal turnover of p21Cip1 does not require p21Cip1 ubiquitination. Mol. Cell. 5, 403-410.
52. Fukuchi,K., Tomoyasu,S., Watanabe,H., Tsuruoka,N. and Gomi,K. (1997) G1 accumulation caused by iron deprivation with deferoxamine does not accompany change of pRB status in ML-1 cells. Biochim. Biophys. Acta, 1357, 297-305.
53. Richardson,D.R., Ponka,P. and Baker,E. (1994) The effect of the iron(III) chelator, desferrioxamine, on iron and transferrin uptake by the human malignant melanoma cell. Cancer Res., 54, 685-689.
54. Lloyd,J.B., Cable,H. and Rice-Evans,C. (1991) Evidence that desferrioxamine cannot enter cells by passive diffusion. Biochem. Pharmacol., 41, 1361-1363.
55. Cable,H. and Lloyd,J.B. (1999) Cellular uptake and release of two contrasting iron chelators. J. Pharmacol., 51, 131-134.